China
Porton Advanced Secures China Commercial Manufacturing Licence for Cell and Gene Therapy CDMO Services
Porton Advanced Solutions Ltd. ("Porton Advanced") has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Admi...
August 07, 2026 | News
Innovent Doses First Patient in Phase 3 Trial of IBI363 for Advanced Colorectal Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
August 07, 2026 | News
Pathos AI Secures Up to $2.2 Billion Global Licensing Deal for Alphamab's First-in-Class Bispecific ADC
Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Al...
August 06, 2026 | News
Kelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblas...
August 03, 2026 | News
Ractigen's World's First saRNA Therapy for Ocular Diseases Advances to Global Clinical Development Following U.S. FDA IND Clearance
RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy f...
August 03, 2026 | News
Ractigen Therapeutics Raises Over $31 Million to Advance saRNA Drug Pipeline
Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery syste...
July 31, 2026 | News
Torrey Pines Medicine Raises Angel Funding to Advance Ultra-Long-Acting Peptide Therapies
Led by Lotus Lake Capital, the financing will accelerate the development of TPM004, a differentiated ultra-long-acting amylin/calcitonin receptor dual agon...
July 30, 2026 | News
Harbour BioMed and Sinopharm Form Strategic Alliance to Accelerate Innovative Biologics
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...
July 29, 2026 | News
Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumours
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...
July 29, 2026 | News
AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...
July 29, 2026 | News
Asymchem Achieves First USFDA Inspection Milestone for Carbapenem API Manufacturing Facility
Asymchem, a leading global contract development and manufacturing organization (CDMO), announced that its dedicated carbapenem API manufacturing facil...
July 28, 2026 | News
7 Countries Competing to Be the Region’s Next Biomanufacturing Hub
A siting decision for a biomanufacturing facility is one of the most expensive commitments a company makes, and it is made against a fifteen to twenty year...
July 27, 2026 | Analysis
Harbour BioMed Forecasts Record H1 2026 Profit as Strategic Partnerships Drive Growth
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutic...
July 27, 2026 | Company results
Ribo’s Vortosiran Achieves 92% FXI Activity Reduction in Phase 2a Coronary Artery Disease Study
Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at C...
July 24, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
